Publicação

Development of PEGylated nanoparticles for delivery of methotrexate derivatives

Ver documento

Detalhes bibliográficos
Resumo:Cancer is one of the most devastating and life-threatening diseases, and conventional chemotherapeutic agents, such as methotrexate (MTX), present several limitations and adverse effects. The use of nanoparticles (NPs) enables an efficient alternative to conventional therapy as they can overcome these limitations. NPs may be engineered to have a prolonged circulation time, enhanced cellular uptake and targeting abilities. One widely used targeting approach is the development of NPs containing folic acid (FA) at the surface. Folate receptor (FR) is overexpressed in tumor cells and is not expressed or is present at low levels in normal cells. In this way, FA-tagged NPs allow a specific delivery of the drug. Although several types of NPs have been developed as drug delivery systems (DDS), this work focused on the polymeric micelles and liposomes. Thus, the main aim of this project was the development of PEGylated micelles and liposomes with suitable characteristics for intravenous (IV) administration and with the ability to delivery hydrophobic MTX derivatives to a target cell population. First of all, micelles and liposomes production methods were optimized. For the micelles production were tested two different methods, auxiliary solvent method and sonication, and the liposomes were produced using ethanol injection method. The full characterization of the developed NPs was performed, including the analysis of their physicochemical properties, stability, drug encapsulation efficiency (EE) and biological effect. The use of the auxiliary solvent method with evaporation at 30 ºC, a polyoxyethanyl-α-tocopheryl sebacate (PTS) concentration of 15 mg/mL and a PTS/MTX diethylated (MTX-OEt) mass ratio of 8:1 resulted in monodisperse micelles with small size. These PEGylated micelles revealed the expected biological effect against cancer cells (Caco-2 cells). In the case of liposomes, the ideal formulation was reached using a lipid concentration of 9 mM, water as aqueous phase, a MTXdimethyldioctadecylammonium bromide (MTX-DODAB) concentration of 2.91 mg/mL and an initial water/ethanol volume of 6/6 mL. The obtained liposomes also showed suitable characteristics including a monodisperse population of small and neutral particles and demonstrated a significant cytotoxicity against cancer cells, similar to free MTX. In sum, the developed PEGylated micelles and liposomes loaded with hydrophobic MTX derivatives demonstrated to be promising DDS for cancer therapy.
Autores principais:Cerqueira, Patrícia Alexandra Gomes
Ano:2018
País:Portugal
Tipo de documento:dissertação de mestrado
Tipo de acesso:acesso aberto
Instituição associada:Universidade do Minho
Idioma:inglês
Origem:RepositóriUM - Universidade do Minho
_version_ 1866876175246163968
author Cerqueira, Patrícia Alexandra Gomes
author_facet Cerqueira, Patrícia Alexandra Gomes
author_role author
contributor_name_str_mv Loureiro, Ana Isabel Sá
Marcos, João Carlos
Universidade do Minho
country_str PT
creators_json_txt [{\"Person.name\":\"Cerqueira, Patrícia Alexandra Gomes\"}]
datacite.contributors.contributor.contributorName.fl_str_mv Loureiro, Ana Isabel Sá
Marcos, João Carlos
Universidade do Minho
datacite.creators.creator.creatorName.fl_str_mv Cerqueira, Patrícia Alexandra Gomes
datacite.date.Accepted.fl_str_mv 2018-01-01T00:00:00Z
datacite.date.available.fl_str_mv 2022-01-01T07:00:36Z
datacite.date.embargoed.fl_str_mv 2022-01-01T07:00:36Z
datacite.rights.fl_str_mv http://purl.org/coar/access_right/c_abf2
datacite.titles.title.fl_str_mv Development of PEGylated nanoparticles for delivery of methotrexate derivatives
Desenvolvimento de nanopartículas peguiladas para a entrega de derivados de metotrexato
dc.contributor.none.fl_str_mv Loureiro, Ana Isabel Sá
Marcos, João Carlos
Universidade do Minho
dc.creator.none.fl_str_mv Cerqueira, Patrícia Alexandra Gomes
dc.date.Accepted.fl_str_mv 2018-01-01T00:00:00Z
dc.date.available.fl_str_mv 2022-01-01T07:00:36Z
dc.date.embargoed.fl_str_mv 2022-01-01T07:00:36Z
dc.format.none.fl_str_mv application/pdf
dc.identifier.none.fl_str_mv https://hdl.handle.net/1822/65119
dc.language.none.fl_str_mv eng
dc.rights.none.fl_str_mv http://purl.org/coar/access_right/c_abf2
dc.title.fl_str_mv Development of PEGylated nanoparticles for delivery of methotrexate derivatives
Desenvolvimento de nanopartículas peguiladas para a entrega de derivados de metotrexato
dc.type.none.fl_str_mv http://purl.org/coar/resource_type/c_bdcc
description Cancer is one of the most devastating and life-threatening diseases, and conventional chemotherapeutic agents, such as methotrexate (MTX), present several limitations and adverse effects. The use of nanoparticles (NPs) enables an efficient alternative to conventional therapy as they can overcome these limitations. NPs may be engineered to have a prolonged circulation time, enhanced cellular uptake and targeting abilities. One widely used targeting approach is the development of NPs containing folic acid (FA) at the surface. Folate receptor (FR) is overexpressed in tumor cells and is not expressed or is present at low levels in normal cells. In this way, FA-tagged NPs allow a specific delivery of the drug. Although several types of NPs have been developed as drug delivery systems (DDS), this work focused on the polymeric micelles and liposomes. Thus, the main aim of this project was the development of PEGylated micelles and liposomes with suitable characteristics for intravenous (IV) administration and with the ability to delivery hydrophobic MTX derivatives to a target cell population. First of all, micelles and liposomes production methods were optimized. For the micelles production were tested two different methods, auxiliary solvent method and sonication, and the liposomes were produced using ethanol injection method. The full characterization of the developed NPs was performed, including the analysis of their physicochemical properties, stability, drug encapsulation efficiency (EE) and biological effect. The use of the auxiliary solvent method with evaporation at 30 ºC, a polyoxyethanyl-α-tocopheryl sebacate (PTS) concentration of 15 mg/mL and a PTS/MTX diethylated (MTX-OEt) mass ratio of 8:1 resulted in monodisperse micelles with small size. These PEGylated micelles revealed the expected biological effect against cancer cells (Caco-2 cells). In the case of liposomes, the ideal formulation was reached using a lipid concentration of 9 mM, water as aqueous phase, a MTXdimethyldioctadecylammonium bromide (MTX-DODAB) concentration of 2.91 mg/mL and an initial water/ethanol volume of 6/6 mL. The obtained liposomes also showed suitable characteristics including a monodisperse population of small and neutral particles and demonstrated a significant cytotoxicity against cancer cells, similar to free MTX. In sum, the developed PEGylated micelles and liposomes loaded with hydrophobic MTX derivatives demonstrated to be promising DDS for cancer therapy.
dirty 0
eu_rights_str_mv openAccess
format masterThesis
fulltext.url.fl_str_mv https://prod-dspace.uminho.pt/bitstreams/71c084a2-1888-4c56-a70f-8a759f0f7e98/download
id rum_1f712673acbca0c75ea985d971bcaa1e
identifier.url.fl_str_mv https://hdl.handle.net/1822/65119
instacron_str repositorium
institution Universidade do Minho
instname_str Universidade do Minho
language eng
network_acronym_str rum
network_name_str RepositóriUM - Universidade do Minho
oai_identifier_str oai:repositorium.uminho.pt:1822/65119
organization_str_mv urn:organizationAcronym:repositorium
person_str_mv Cerqueira, Patrícia Alexandra Gomes
publishDate 2018
reponame_str RepositóriUM - Universidade do Minho
repository_id_str urn:repositoryAcronym:rum
service_str_mv urn:repositoryAcronym:rum
spelling engporCancer is one of the most devastating and life-threatening diseases, and conventional chemotherapeutic agents, such as methotrexate (MTX), present several limitations and adverse effects. The use of nanoparticles (NPs) enables an efficient alternative to conventional therapy as they can overcome these limitations. NPs may be engineered to have a prolonged circulation time, enhanced cellular uptake and targeting abilities. One widely used targeting approach is the development of NPs containing folic acid (FA) at the surface. Folate receptor (FR) is overexpressed in tumor cells and is not expressed or is present at low levels in normal cells. In this way, FA-tagged NPs allow a specific delivery of the drug. Although several types of NPs have been developed as drug delivery systems (DDS), this work focused on the polymeric micelles and liposomes. Thus, the main aim of this project was the development of PEGylated micelles and liposomes with suitable characteristics for intravenous (IV) administration and with the ability to delivery hydrophobic MTX derivatives to a target cell population. First of all, micelles and liposomes production methods were optimized. For the micelles production were tested two different methods, auxiliary solvent method and sonication, and the liposomes were produced using ethanol injection method. The full characterization of the developed NPs was performed, including the analysis of their physicochemical properties, stability, drug encapsulation efficiency (EE) and biological effect. The use of the auxiliary solvent method with evaporation at 30 ºC, a polyoxyethanyl-α-tocopheryl sebacate (PTS) concentration of 15 mg/mL and a PTS/MTX diethylated (MTX-OEt) mass ratio of 8:1 resulted in monodisperse micelles with small size. These PEGylated micelles revealed the expected biological effect against cancer cells (Caco-2 cells). In the case of liposomes, the ideal formulation was reached using a lipid concentration of 9 mM, water as aqueous phase, a MTXdimethyldioctadecylammonium bromide (MTX-DODAB) concentration of 2.91 mg/mL and an initial water/ethanol volume of 6/6 mL. The obtained liposomes also showed suitable characteristics including a monodisperse population of small and neutral particles and demonstrated a significant cytotoxicity against cancer cells, similar to free MTX. In sum, the developed PEGylated micelles and liposomes loaded with hydrophobic MTX derivatives demonstrated to be promising DDS for cancer therapy.application/pdfengDevelopment of PEGylated nanoparticles for delivery of methotrexate derivativesAlternativeTitleporDesenvolvimento de nanopartículas peguiladas para a entrega de derivados de metotrexatoCerqueira, Patrícia Alexandra GomesLoureiro, Ana Isabel SáMarcos, João CarlosHostingInstitutionOrganizationalUniversidade do Minhoe-mailmailto:repositorium@usdb.uminho.ptrepositorium@usdb.uminho.ptURNurn:tid:2022786892022-01-01T07:00:36Z201820182018-01-01T00:00:00ZHandlehttps://hdl.handle.net/1822/65119http://purl.org/coar/access_right/c_abf2open access3319969 bytesliteraturehttp://purl.org/coar/resource_type/c_bdccmaster thesishttp://purl.org/coar/access_right/c_abf2application/pdffulltexthttps://prod-dspace.uminho.pt/bitstreams/71c084a2-1888-4c56-a70f-8a759f0f7e98/download
spellingShingle Development of PEGylated nanoparticles for delivery of methotrexate derivatives
Cerqueira, Patrícia Alexandra Gomes
status SINGLETON
title Development of PEGylated nanoparticles for delivery of methotrexate derivatives
title_full Development of PEGylated nanoparticles for delivery of methotrexate derivatives
title_fullStr Development of PEGylated nanoparticles for delivery of methotrexate derivatives
title_full_unstemmed Development of PEGylated nanoparticles for delivery of methotrexate derivatives
title_short Development of PEGylated nanoparticles for delivery of methotrexate derivatives
title_sort Development of PEGylated nanoparticles for delivery of methotrexate derivatives
url https://hdl.handle.net/1822/65119
visible 1